Abstract: A wearable health management system includes a flexible member configured to be worn on an affected area by a patient. At least one actuator is operably coupled to the flexible member. The at least one actuator is configured to be adjusted between a deployed state and a non-deployed state. At least one of a photoplethysmogram sensor and a bioimpedance sensor is coupled to the flexible member to obtain one or more health metrics from the patient. A controller is in communication with the at least one actuator. The controller is configured to adjust the at least one actuator to the deployed state to provide a selected pressure to the affected area.

Abstract: A blower includes a housing including an inlet and an outlet, a bearing-housing structure provided to the housing and adapted to rotatably support a rotor, a motor provided to the bearing-housing structure and adapted to drive the rotor, and an impeller provided to the rotor. The bearing-housing structure includes a bearing shaft having a bearing surface that rotatably supports the rotor. The bearing shaft provides only a single bearing of the non-ball bearing type for the rotor.

Abstract: A device for permanent placement across an atrial appendage ostium in a patient includes a support structure having a contracted delivery configuration and an expanded deployed configuration defining a radially enlarged portion to permanently engage an interior wall of the atrial appendage, a membrane attached to the support structure and configured to extend across the ostium of the atrial appendage when the support structure is in the expanded deployed configuration, and a polymer coating disposed on at least one of the support structure and the membrane, the polymer coating including a direct oral anticoagulant (DOAC) dispersed in a polymer.

Abstract: Tissue access devices and methods of using the same are disclosed. The devices can have a sensor configured to occlude a flow path by deflecting a membrane into the flow path when the devices become dislodged from tissue. The sensor can be configured to partially or fully occlude the flow path. The sensor can have a spring. The spring can be biased to move the sensor from a sensor first configuration to a sensor second configuration when a force applied by the sensor first surface against a non-sensor surface changes from a first force to a second force less than the first force. The membrane can be deflected into the flow path when the sensor is in the sensor second configuration.

Abstract: A wearable health management system includes a flexible member configured to be worn on an affected area by a patient. At least one actuator is operably coupled to the flexible member. The at least one actuator is configured to be adjusted between a deployed state and a non-deployed state. At least one of a photoplethysmogram sensor and a bioimpedance sensor is coupled to the flexible member to obtain one or more health metrics from the patient. A controller is in communication with the at least one actuator. The controller is configured to adjust the at least one actuator to the deployed state to provide a selected pressure to the affected area.

Abstract: Various embodiments of the present invention are directed to a device for the reduction perceived pain in patients. Various embodiments comprise a flexible shell comprising a pliable material and a first non-planar surface and a second surface opposite the first surface. The flexible shell defines an interior cavity located intermediate the first surface and the second surface and filled at least in part by a first substance. The first surface comprises a plurality of protrusions distributed therein and configured to be depressed into the skin of the patient. The pain reducing device may execute a cooling functionality upon being moved from a first position to a second position. When cooled and depressed against the patient's skin, the pain reducing device provides a sensory confusion sensation to the patient, thereby reducing perceived pain caused by a needle insertion.

Abstract: Various embodiments of the present invention are directed to a device for the reduction of needle insertion site pain in patients. Various embodiments comprise a shell defining a hollow interior cavity filled at least in part by a freezable substance. The shell defines a first surface and a second surface opposite the first surface, and a passage extending through the shell between the first surface and the second surface, wherein the passage is configured to at least partially surround a needle insertion site while a needle is inserted therethrough. At least one of the first and second surfaces comprise a plurality of protrusions distributed therein and configured to be depressed into the skin of the patient. When chilled and depressed against the patient's skin, the freezable device provides a sensory confusion sensation to the patient, thereby reducing perceived pain caused by the needle insertion.

Abstract: A communications hub receives a messaging job creation request sent over a network connection. The messaging job creation request includes a destinations uniform resource locator (“URL”) plus an inline contents list containing content specifiers, a contents URL plus an inline destinations list containing recipient specifiers, or a destinations URL plus a contents URL. The destinations URL identifies a list of recipient specifiers, each with a delivery address and mode. The contents URL identifies content specifiers for content to be delivered. Some recipient specifiers include merge fields for merging values into message contents. The contents URL itself may include a merge field for merging to obtain a merged contents URL which then identifies a content specifier location. The URLs and the merge fields can appear in various combinations, thereby supporting flexible message customization without hindering bulk messaging.

Abstract: Various implementations of the present invention are provided as a network computer system configured to allow for creating, rating, tracking, monitoring, and disseminating user-created and user-customizable messages. The network computer system provides a user interface that allows a user to create templates for message creation, messages from the templates, ratings for messages (message “bias”), databases for storing templates and messages (message queue), and ratings, as well as storage for information related to the monitoring and tracking of messages as they are delivered to the intended recipients. The ability to create multiple messages, with disparate content, intended for disparate audiences, with batch sorting and sending, is also provided. Messages can be provided via commercial messaging services such as email, snail mail, telephone, SMS, facsimile, social media networking sites (e.g. Facebook® messages, Twitter® “tweets”, etc.).

Abstract: The present invention relates to methods and compositions for improved efficacy and delivery of time-dependent antimicrobial drug compositions to a patient. Transdermal dosage forms and methods for steady-state delivery of drug to produce and maintain a serum concentration of drug above the minimum inhibitory concentration or minimum microbicidal concentration are provided.

Abstract: The present invention relates to methods and compositions for improved efficacy and delivery of time-dependent antimicrobial drug compositions to a patient. Transdermal dosage forms and methods for steady-state delivery of drug to produce and maintain a serum concentration of drug above the minimum inhibitory concentration or minimum microbicidal concentration are provided.

Abstract: The present invention relates to the field of medical devices used in orotracheal intubation. The insertion and manipulation of laryngoscopes used by medical personnel may occasionally cause damage or breakage of incisors or other maxillary teeth. The present invention provides a device useful for the prevention of tooth damage occurring with common laryngoscopes and other airway intubation systems. The device comprises an upper mouthguard for the maxillary teeth attached to blocks or wedges for keeping the jaw open. Optionally, a light such as an LED may be incorporated in one of the blocks to facilitate the intubation procedure. The invention is placed into the subject's mouth, and then intubation using a laryngoscope may be safely performed. Once intubation has been accomplished, and the laryngoscope has been removed, the dental guard of this invention may be retained in the patient's jaw as a bite block, or removed, or replaced with another type of bite block.

Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.

Abstract: This invention relates to a method of treating otitis externa, and in particular otitis externa of fungal etiology, using topical medication, including antifungal agents such as itraconazole and miconazole, and optionally also including a second antifungal agent, which is formulated for topical application to the external ear canal, preferably as an ear drop in liquid form.

Abstract: This invention relates to a method of treating otitis externa using a topical combination medication, including one or more antifungal agent such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin, micafungin, terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), nystatin, pimaricin, griseofulvin, ciclopirox, haloprogin, tolnaftate, and undecylenate and one or more antibacterial agent such as neomycin sulfate, polymyxin B sulfate, colistin sulfate, gentamycin, tobramycin, chloramphenicol, ciprofloxacin, ofloxacin, a penicillin compound, a cephalosporin compound, a macrolide compound, a fluoroquinolone compound, streptomycin, or kanamycin.

Abstract: The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) a mucosal adjuvant, (3) an antihistamine drug and (4) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, a topical steroid or a leukotriene blocker.

Abstract: The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) an antihistamine drug and (3) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, a topical steroid or a leukotriene blocker.

Abstract: The present invention relates to methods and compositions for improved efficacy and delivery of time-dependent antimicrobial drug compositions to a patient. Transdermal dosage forms and methods for steady-state delivery of drug to produce and maintain a serum concentration of drug above the minimum inhibitory concentration or minimum microbicidal concentration are provided.

Abstract: The present invention relates to dual nasal spray applicator devices and systems for administration of two nasal compositions in one spray or aerosol dose without mixing of the compositions prior to administration and methods of treatment using these devices and systems. The devices allow incompatible drug or other compositions to be stored and administered by a single device in a single dose, remaining separated until just prior to or during administration of the medications.

Abstract: The present invention relates to compositions and methods for initial treatment of GERD and LPRD using a proton pump inhibitor drug administered concomitantly with a histamine H2 receptor inhibitor, either transdermally or orally.